Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 281

1.

Brief Report: Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced Non-Small Cell Lung Cancer and Response to Osimertinib versus Comparator in FLAURA.

Brown H, Vansteenkiste J, Nakagawa K, Cobo M, John T, Barker C, Kohlmann A, Todd A, Saggese M, Chmielecki J, Markovets A, Scott M, Ramalingam SS.

J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33334-9. doi: 10.1016/j.jtho.2019.09.009. [Epub ahead of print]

PMID:
31605792
2.

A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.

Besse B, Barlesi F, Demedts I, Fuentes Pradera J, Robinet G, Gazzah A, Soldatenkova V, Frimodt-Moller B, Kim JS, Vansteenkiste J.

Lung Cancer. 2019 Sep 3;137:136-143. doi: 10.1016/j.lungcan.2019.09.002. [Epub ahead of print]

PMID:
31586771
3.

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small cell lung cancer with a PD-L1 expression level of ≥ 1% by the U.S. Food and Drug Administration.

Mountzios G, Remon J, Novello S, Blais N, Califano R, Cufer T, Dingemans AM, Liu SV, Peled N, Pennell NA, Reck M, Rolfo C, Tan D, Vansteenkiste J, West H, Besse B.

Ann Oncol. 2019 Sep 3. pii: mdz295. doi: 10.1093/annonc/mdz295. [Epub ahead of print] No abstract available.

PMID:
31504132
4.

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Gray JE, Okamoto I, Sriuranpong V, Vansteenkiste J, Imamura F, Lee JS, Pang YK, Cobo M, Kasahara K, Cheng Y, Nogami N, Cho EK, Su WC, Zhang G, Huang X, Li-Sucholeiki X, Lentrichia B, Dearden S, Jenkins S, Saggese M, Rukazenkov Y, Ramalingam SS.

Clin Cancer Res. 2019 Aug 22. doi: 10.1158/1078-0432.CCR-19-1126. [Epub ahead of print]

PMID:
31439584
5.

Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report.

Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, Giaj-Levra M, Giaj-Levra N, Girard N, Greillier L, Lantuéjoul S, Edwards J, O'Brien M, Reck M, Smit EF, Van Schil P, Postmus PE, Ramella S, Lievens Y, Gaga M, Peled N, Scagliotti GV, Senan S, Paz-Ares L, Guckenberger M, McDonald F, Ekman S, Cufer T, Gietema H, Infante M, Dziadziuszko R, Peters S, Porta RR, Vansteenkiste J, Dooms C, de Ruysscher D, Besse B, Novello S.

J Thorac Oncol. 2019 Aug 6. pii: S1556-0864(19)30655-0. doi: 10.1016/j.jtho.2019.07.025. [Epub ahead of print]

PMID:
31398540
6.

Capmatinib for the treatment of non-small cell lung cancer.

Vansteenkiste JF, Van De Kerkhove C, Wauters E, Van Mol P.

Expert Rev Anticancer Ther. 2019 Aug;19(8):659-671. doi: 10.1080/14737140.2019.1643239. Epub 2019 Aug 1.

PMID:
31368815
7.

ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.

Marinis F, Wu YL, de Castro G Jr, Chang GC, Chen YM, Cho BC, Freitas HC, Jiang L, Kim SW, Martin C, Metro G, Provencio M, Vansteenkiste J, Vicente D, Zhou Q, Miranda MF, Bakker NA, Rigas JR, Cheema PK.

Future Oncol. 2019 Sep;15(26):3003-3014. doi: 10.2217/fon-2019-0324. Epub 2019 Jul 24.

PMID:
31339357
8.

The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History.

Mignon S, Willard-Gallo K, Van den Eynden G, Salgado R, Decoster L, Marien KM, Vansteenkiste JF, Teugels E, De Grève J.

Pathol Oncol Res. 2019 Jun 21. doi: 10.1007/s12253-019-00670-9. [Epub ahead of print]

PMID:
31228073
9.

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.

Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Tufman A, Lambrecht M, Andratschke N, Piguet AC, Kassapian M, Roschitzki-Voser H, Rabaglio-Poretti M, Stahel RA, Vansteenkiste J, De Ruysscher D.

Lung Cancer. 2019 Jul;133:83-87. doi: 10.1016/j.lungcan.2019.05.001. Epub 2019 May 3.

PMID:
31200833
10.

Current status of immune checkpoint inhibition in early stage NSCLC.

Vansteenkiste J, Wauters E, Reymen B, Ackermann CJ, Peters S, De Ruysscher D.

Ann Oncol. 2019 May 28. pii: mdz175. doi: 10.1093/annonc/mdz175. [Epub ahead of print]

PMID:
31143921
11.

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.

van Brummelen EMJ, Levchenko E, Dómine M, Fennell DA, Kindler HL, Viteri S, Gadgeel S, López PG, Kostorov V, Morgensztern D, Orlov S, Zauderer MG, Vansteenkiste JF, Baker-Neblett K, Vasquez J, Wang X, Bellovin DI, Schellens JHM, Yan L, Mitrica I, DeYoung MP, Trigo J.

Invest New Drugs. 2019 May 7. doi: 10.1007/s10637-019-00783-7. [Epub ahead of print]

PMID:
31065954
12.

Author Correction: CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells.

Kim J, Hu Z, Cai L, Li K, Choi E, Faubert B, Bezwada D, Rodriguez-Canales J, Villalobos P, Lin YF, Ni M, Huffman KE, Girard L, Byers LA, Unsal-Kacmaz K, Peña CG, Heymach JV, Wauters E, Vansteenkiste J, Castrillon DH, Chen BPC, Wistuba I, Lambrechts D, Xu J, Minna JD, DeBerardinis RJ.

Nature. 2019 May;569(7756):E4. doi: 10.1038/s41586-019-1133-3.

PMID:
31043737
13.

A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.

Kerr KM, Thunnissen E, Dafni U, Finn SP, Bubendorf L, Soltermann A, Verbeken E, Biernat W, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Radonic T, Wilson J, De Luca G, Gray SG, Cheney R, Savic S, Martorell M, Muley T, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dziadziuszko R, Vansteenkiste J, Weder W, Polydoropoulou V, Geiger T, Kammler R, Peters S, Stahel R; Lungscape Consortium.

Lung Cancer. 2019 May;131:95-103. doi: 10.1016/j.lungcan.2019.03.012. Epub 2019 Mar 15.

PMID:
31027705
14.

Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study.

Cho BC, DE Pas T, Kalofonos H, Wang Q, Ramlau R, Cheng Y, Vitiello F, Laisaar T, Vallières E, Kubisa B, Orlov S, Park K, Debruyne C, Vansteenkiste J.

Anticancer Res. 2019 Mar;39(3):1403-1409. doi: 10.21873/anticanres.13255.

PMID:
30842175
15.

Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy.

Frick AE, Nackaerts K, Moons J, Lievens Y, Verbeken E, Lambrecht M, Coolen J, Dooms C, Vansteenkiste J, De Leyn P, Nafteux P.

Eur J Cardiothorac Surg. 2019 May 1;55(5):934-941. doi: 10.1093/ejcts/ezy385.

PMID:
30535191
16.

Immune checkpoint inhibitors for every patient with non-small cell lung cancer? Update on immunotherapy in patients with lung cancer.

Vansteenkiste JF.

ESMO Open. 2018 Sep 10;3(6):e000429. doi: 10.1136/esmoopen-2018-000429. eCollection 2018. No abstract available.

17.

Immunotherapy in patients with early stage resectable nonsmall cell lung cancer.

Ghysen K, Vansteenkiste J.

Curr Opin Oncol. 2019 Jan;31(1):13-17. doi: 10.1097/CCO.0000000000000497.

PMID:
30325753
18.

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators.

N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.

PMID:
30280658
19.

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.

Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F, Özgüroğlu M, Szczesna A, Polychronis A, Uslu R, Krzakowski M, Lee JS, Calabrò L, Arén Frontera O, Ellers-Lenz B, Bajars M, Ruisi M, Park K.

Lancet Oncol. 2018 Nov;19(11):1468-1479. doi: 10.1016/S1470-2045(18)30673-9. Epub 2018 Sep 24. Erratum in: Lancet Oncol. 2018 Nov;19(11):e581.

PMID:
30262187
20.

Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin.

Harvey RD, Aransay NR, Isambert N, Lee JS, Arkenau T, Vansteenkiste J, Dickinson PA, Bui K, Weilert D, So K, Thomas K, Vishwanathan K.

Br J Clin Pharmacol. 2018 Dec;84(12):2877-2888. doi: 10.1111/bcp.13753. Epub 2018 Oct 10.

PMID:
30171779
21.

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

Wu YL, Zhang L, Kim DW, Liu X, Lee DH, Yang JC, Ahn MJ, Vansteenkiste JF, Su WC, Felip E, Chia V, Glaser S, Pultar P, Zhao S, Peng B, Akimov M, Tan DSW.

J Clin Oncol. 2018 Nov 1;36(31):3101-3109. doi: 10.1200/JCO.2018.77.7326. Epub 2018 Aug 29. Erratum in: J Clin Oncol. 2019 Jan 20;37(3):261.

PMID:
30156984
22.

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J.

J Clin Oncol. 2018 Aug 28:JCO2018783118. doi: 10.1200/JCO.2018.78.3118. [Epub ahead of print]

PMID:
30153097
23.

RNA-sequencing in non-small cell lung cancer shows gene downregulation of therapeutic targets in tumor tissue compared to non-malignant lung tissue.

Reynders K, Wauters E, Moisse M, Decaluwé H, De Leyn P, Peeters S, Lambrecht M, Nackaerts K, Dooms C, Janssens W, Vansteenkiste J, Lambrechts D, De Ruysscher D.

Radiat Oncol. 2018 Jul 17;13(1):131. doi: 10.1186/s13014-018-1075-1.

24.

Phenotype molding of stromal cells in the lung tumor microenvironment.

Lambrechts D, Wauters E, Boeckx B, Aibar S, Nittner D, Burton O, Bassez A, Decaluwé H, Pircher A, Van den Eynde K, Weynand B, Verbeken E, De Leyn P, Liston A, Vansteenkiste J, Carmeliet P, Aerts S, Thienpont B.

Nat Med. 2018 Aug;24(8):1277-1289. doi: 10.1038/s41591-018-0096-5. Epub 2018 Jul 9.

PMID:
29988129
25.

A Randomized Clinical Trial of Flex 19G Needles versus 22G Needles for Endobronchial Ultrasonography in Suspected Lung Cancer.

Dooms C, Vander Borght S, Yserbyt J, Testelmans D, Wauters E, Nackaerts K, Vansteenkiste J, Verbeken E, Weynand B.

Respiration. 2018;96(3):275-282. doi: 10.1159/000489473. Epub 2018 Jun 29.

PMID:
29961053
26.

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.

Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA Jr, Culligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello S, Pérol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Vansteenkiste JF, Wakelee H, Thatcher N.

Ann Oncol. 2018 Aug 1;29(8):1701-1709. doi: 10.1093/annonc/mdy196.

27.

Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?

Deslypere G, Gullentops D, Wauters E, Vansteenkiste J.

Ther Adv Med Oncol. 2018 May 4;10:1758835918772810. doi: 10.1177/1758835918772810. eCollection 2018. Review.

28.

Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies.

Hirsch FR, Kerr KM, Bunn PA Jr, Kim ES, Obasaju C, Pérol M, Bonomi P, Bradley JD, Gandara D, Jett JR, Langer CJ, Natale RB, Novello S, Paz-Ares L, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Stinchcombe TE, Vansteenkiste JF, Wakelee H, Thatcher N.

Clin Lung Cancer. 2018 Jul;19(4):331-339. doi: 10.1016/j.cllc.2018.03.014. Epub 2018 Mar 21. Review.

29.

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators.

Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.

PMID:
29545095
30.

Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years.

Vansteenkiste J, Wauters E.

Ann Oncol. 2018 Jan 1;29(suppl_1):i1-i2. doi: 10.1093/annonc/mdx724. No abstract available.

PMID:
29462258
31.

Is central lung tumour location really predictive for occult mediastinal nodal disease in (suspected) non-small-cell lung cancer staged cN0 on 18F-fluorodeoxyglucose positron emission tomography-computed tomography?

Decaluwé H, Moons J, Fieuws S, De Wever W, Deroose C, Stanzi A, Depypere L, Nackaerts K, Coolen J, Lambrecht M, Verbeken E, De Ruysscher D, Vansteenkiste J, Van Raemdonck D, De Leyn P, Dooms C; Leuven Lung Cancer Group.

Eur J Cardiothorac Surg. 2018 Jul 1;54(1):134-140. doi: 10.1093/ejcts/ezy018.

PMID:
29447330
32.

Genetic profiling of cell-free DNA from cerebrospinal fluid: opening the barrier to leptomeningeal metastasis in EGFR-mutant NSCLC.

Vanden Bempt I, Wauters E, Vansteenkiste J.

Ann Oncol. 2018 Apr 1;29(4):789-791. doi: 10.1093/annonc/mdy053. No abstract available.

PMID:
29432543
33.

Immunotherapy in lung cancer.

Vansteenkiste JF.

ESMO Open. 2018 Jan 9;3(1):e000311. doi: 10.1136/esmoopen-2017-000311. eCollection 2018. No abstract available.

34.

Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project.

Letovanec I, Finn S, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel EJ, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernandez-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Navarro A, Felip E, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dienemann H, Dziadziuszko R, Vansteenkiste J, O'Brien C, Geiger T, Sherlock J, Schageman J, Dafni U, Kammler R, Kerr K, Thunnissen E, Stahel R, Peters S; European Thoracic Oncology Platform Lungscape Consortium.

J Thorac Oncol. 2018 Mar;13(3):413-425. doi: 10.1016/j.jtho.2017.11.117. Epub 2017 Nov 27.

35.

Will liquid biopsies become our fluid transition to personalized immunotherapy?

Wauters E, Vansteenkiste J.

Ann Oncol. 2018 Jan 1;29(1):11-13. doi: 10.1093/annonc/mdx751. No abstract available.

PMID:
29165546
36.

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators.

N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.

37.

Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis.

Vansteenkiste J.

ESMO Open. 2017 Mar 7;2(Suppl 1):e000119. doi: 10.1136/esmoopen-2016-000119. eCollection 2017. No abstract available.

38.

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C, Peters S; ESMO Guidelines Committee.

Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21. doi: 10.1093/annonc/mdx222. No abstract available.

PMID:
28881918
39.

Geriatric Assessment and Functional Decline in Older Patients with Lung Cancer.

Decoster L, Kenis C, Schallier D, Vansteenkiste J, Nackaerts K, Vanacker L, Vandewalle N, Flamaing J, Lobelle JP, Milisen K, De Grève J, Wildiers H.

Lung. 2017 Oct;195(5):619-626. doi: 10.1007/s00408-017-0025-2. Epub 2017 Jun 20.

PMID:
28634893
40.

CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells.

Kim J, Hu Z, Cai L, Li K, Choi E, Faubert B, Bezwada D, Rodriguez-Canales J, Villalobos P, Lin YF, Ni M, Huffman KE, Girard L, Byers LA, Unsal-Kacmaz K, Peña CG, Heymach JV, Wauters E, Vansteenkiste J, Castrillon DH, Chen BPC, Wistuba I, Lambrechts D, Xu J, Minna JD, DeBerardinis RJ.

Nature. 2017 Jun 1;546(7656):168-172. doi: 10.1038/nature22359. Epub 2017 May 24. Erratum in: Nature. 2019 May;569(7756):E4.

41.

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.

Jänne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crinò L, Orlov S, Blackhall F, Wolf J, Garrido P, Poltoratskiy A, Mariani G, Ghiorghiu D, Kilgour E, Smith P, Kohlmann A, Carlile DJ, Lawrence D, Bowen K, Vansteenkiste J.

JAMA. 2017 May 9;317(18):1844-1853. doi: 10.1001/jama.2017.3438.

42.

Prospects and progress of atezolizumab in non-small cell lung cancer.

Vansteenkiste J, Wauters E, Park K, Rittmeyer A, Sandler A, Spira A.

Expert Opin Biol Ther. 2017 Jun;17(6):781-789. doi: 10.1080/14712598.2017.1309389. Epub 2017 Mar 28. Review.

PMID:
28335643
43.

The challenge of molecular testing for clinical trials in advanced non-small cell lung cancer patients: Analysis of a prospective database.

Vrancken A, Lepers S, Peeters L, Oyen C, Dooms C, Nackaerts K, Verbeken E, Wauters I, Weynand B, Vansteenkiste J.

Lung Cancer. 2016 Dec;102:96-100. doi: 10.1016/j.lungcan.2016.11.003. Epub 2016 Nov 6.

PMID:
27987596
44.

Postoperative radiotherapy for lung cancer: Is it worth the controversy?

Billiet C, Peeters S, Decaluwé H, Vansteenkiste J, Mebis J, Ruysscher D.

Cancer Treat Rev. 2016 Dec;51:10-18. doi: 10.1016/j.ctrv.2016.10.001. Epub 2016 Oct 14. Review.

PMID:
27788387
45.

A 65-Year-Old Patient with Superior Vena Cava Syndrome and Bone Metastases.

De Maeyer N, De Wever W, Deroose CM, Vansteenkiste J.

J Thorac Oncol. 2016 Nov;11(11):2033-2035. doi: 10.1016/j.jtho.2016.08.135. Epub 2016 Aug 24. No abstract available.

46.

Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and Resection.

Billiet C, Peeters S, Decaluwé H, Vansteenkiste J, Dooms C, Deroose CM, Hendrikx M, De Leyn P, Bulens P, Karim R, Le Péchoux C, Mebis J, De Ruysscher D.

J Thorac Oncol. 2016 Nov;11(11):1940-1953. doi: 10.1016/j.jtho.2016.06.018. Epub 2016 Jul 5.

47.

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, Kerr K, Popat S, Reck M, Senan S, Simo GV, Vansteenkiste J, Peters S; ESMO Guidelines Committee.

Ann Oncol. 2016 Sep;27(suppl 5):v1-v27. No abstract available.

PMID:
27664245
48.

Patterns of Locoregional Relapses in Patients with Contemporarily Staged Stage III-N2 NSCLC Treated with Induction Chemotherapy and Resection: Implications for Postoperative Radiotherapy Target Volumes.

Billiet C, De Ruysscher D, Peeters S, Decaluwé H, Vansteenkiste J, Dooms C, Deroose CM, De Leyn P, Hendrikx M, Bulens P, Le Péchoux C, Mebis J.

J Thorac Oncol. 2016 Sep;11(9):1538-49. doi: 10.1016/j.jtho.2016.05.037. Epub 2016 Jun 30.

49.

Selective mediastinal node irradiation in non-small cell lung cancer in the IMRT/VMAT era: How to use E(B)US-NA information in addition to PET-CT for delineation?

Peeters ST, Dooms C, Van Baardwijk A, Dingemans AM, Martinussen H, Vansteenkiste J, Decaluwé H, De Leyn P, Yserbyt J, Nackaerts K, De Wever W, Deroose CM, De Ruysscher D.

Radiother Oncol. 2016 Aug;120(2):273-8. doi: 10.1016/j.radonc.2016.05.023. Epub 2016 Jun 10.

PMID:
27291644
50.

Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.

Antonia SJ, Vansteenkiste JF, Moon E.

Am Soc Clin Oncol Educ Book. 2016;35:e450-8. doi: 10.14694/EDBK_158712. Review.

Supplemental Content

Loading ...
Support Center